AI-powered biotech R&D startup BioNexus announced on August 7 that it has secured Seed funding from Bass Ventures and SMB Investment Partners. The company plans to use the investment to enhance the core technology of its AI scientist agent platform, strengthen R&D capabilities, and accelerate business expansion. BioNexus develops an AI-based bio-data intelligence and scientist agent drug-discovery platform with a suite of innovative research tools. Since its founding, it has completed over 30 research projects and built a collaborative network with 15 institutions.
Company Information
Company
BioNexus
About
BioNexus is an AI-powered biotech R&D startup that develops an AI-based bio-data intelligence and scientist agent drug-discovery platform. Its flagship product, Nexus Co-Scientist, utilizes AI to analyze scientific literature and biomedical data to generate research hypotheses. The company has completed over 30 research projects and built a collaborative network with 15 institutions. BioNexus aims to enhance its technology and expand its business through the recent seed funding.
